topshadow

NovoStent Announces Appointment of Rick Randall as Chairman of the Board

Mountain View, CA, June 2, 2011

NovoStent® Corporation announced the appointment of Rick Randall as Chairman of the Board of Directors. Mr. Randall is currently Chairman and CEO of Avantis Medical Systems, Inc. and Chairman of TranS1, Inc. (TSON).

[more...]

NovoStent Announces 6-Month Results of SAMBA Femoropopliteal Trial

Mountain View, CA (BUSINESS WIRE) May 25, 2010

NovoStent® Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease.

[more...]

NovoStent Receives CE Mark for New Class of Endovascular Implant

Mountain View, CA (BUSINESS WIRE) March 1, 2010

NovoStent® Corporation today announced that it has received CE Mark for its SAMBA Stent and Delivery System for the treatment of peripheral artery disease.

[more...]

NovoStent Announces Completion of Enrollment in SAMBA Femoropopliteal Trial

Mountain View, CA (BUSINESS WIRE) September 18, 2009

NovoStent Corporation today announced the completion of enrollment earlier this summer in the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease.

[more...]

NovoStent Announces Implantation of World's Longest Peripheral Stent

Mountain View, CA (BUSINESS WIRE) March 31, 2008

NovoStent Corporation announced today that physicians in Germany have implanted 250 mm stents as part of the company's European clinical trial evaluating the use of NovoStent's peripheral stent in the treatment of superficial femoral and popliteal artery disease.

[more...]

NovoStent Names G. Ray Martin, PhD, President & CEO

Mountain View, CA (BUSINESS WIRE) October 17, 2005

NovoStent Corporation, a medical device company that has developed a novel "anchored" helical stent technology to provide a wide range of vascular therapies, announced today that G. Ray Martin, PhD, has been appointed its President & Chief Executive Officer and a member of its Board of Directors. He will replace Michael Hogendijk, the Company's founder and primary inventor, who will continue as Chief Technical Officer and a member of the Board of Directors.

[more...]